Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model

BACKGROUND: The bisphosphonate, zoledronic acid (ZOL), can inhibit osteoclasts leading to decreased osteoclastogenesis and osteoclast activity in bone. Here, we used a mixed osteolytic/osteoblastic murine model of bone-metastatic prostate cancer, RM1(BM), to determine how inhibiting osteolysis with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Tzong-Tyng, Chan, Jeffrey, Russell, Pamela J., Power, Carl A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095598/
https://www.ncbi.nlm.nih.gov/pubmed/21603655
http://dx.doi.org/10.1371/journal.pone.0019389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095598/
https://www.ncbi.nlm.nih.gov/pubmed/21603655
http://dx.doi.org/10.1371/journal.pone.0019389

Ejemplares similares